Standardized Use of the Anti-tumor Drug in 60 Beijing Hospitals in 2024
- VernacularTitle:2024年北京市60家医院抗肿瘤药物规范使用情况分析
- Author:
Juan YANG
1
;
Chengcheng ZHOU
1
;
Jincheng YANG
1
;
Liming SHI
1
;
Sufei ZHENG
1
;
Wenjing YANG
1
Author Information
1. 国家癌症中心·国家肿瘤临床医学研究中心·中国医学科学院北京协和医学院肿瘤医院 北京 100021
- Publication Type:Journal Article
- Keywords:
hospital;
anti-tumor drug;
standardized use;
quality control;
Beijing
- From:
Chinese Hospital Management
2025;45(6):44-48
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the standardized use of anti-tumor drugs in Beijing hospitals in 2024,and put forward relevant policy suggestions on standardizing the use of anti-tumor drugs.Methods In 2024,Beijing Cancer Quality Control Center organized internal medicine and pharmacy experts to conduct a research on the standardized use of anti-tumor drugs in 556 medical records from 60 hospitals.The evaluation content included pathological diagnosis and tumor staging,treatment process and quality control.Results The evaluation of the use of anti-tumor drugs in 60 hospitals in Beijing found that the main problems of non-standardized use of anti-tumor drugs were incomplete or unsigned informed consent forms;incomplete,un-staged or incorrect staging of tumors;lack of adverse reaction evaluation;incomplete records of drug application on the day of treatment;no reasons given for adjustments in drug dosage and administration methods,and incomplete efficacy evaluation.Conclusion It is necessary to strengthen the training and guidance of medical staff,carry out regular quality control inspections,enhance information construction,establish a multi-disciplinary diagnosis and treatment system,and establish a regular follow-up mechanism,so as to further standardize and improve the standard rate of antitumor drug use in hospitals.
